Filing Details
- Accession Number:
- 0001562180-22-004014
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-12 20:58:58
- Reporting Period:
- 2022-05-10
- Accepted Time:
- 2022-05-12 20:58:58
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1689813 | Biohaven Pharmaceutical Holding Co Ltd. | BHVN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1878290 | C. George Clark | C/O Biohaven Pharmaceuticals, Inc. 215 Church Street New Haven CT 06510 | Vp, Chief Accounting Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Shares | Acquisiton | 2022-05-10 | 2,250 | $53.76 | 8,265 | No | 4 | M | Direct | |
Common Shares | Disposition | 2022-05-10 | 4,200 | $141.50 | 4,065 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Shares | Employee Stock Option (right to buy) | Disposition | 2022-05-10 | 2,250 | $0.00 | 2,250 | $53.76 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
2,250 | 2029-12-05 | No | 4 | M | Direct |
Footnotes
- These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- The shares underlying this option vest in four equal installments on December 5, 2019, 2020, 2021 and 2022, subject to the reporting person's continued service with the issuer at each vesting date.